Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation (CSP#468F)

This study has been completed.
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
VA Office of Research and Development Identifier:
First received: November 25, 2009
Last updated: May 13, 2015
Last verified: May 2015
Follow up of patients enrolled in CSP 468, a study of deep brain stimulation treatment for Parkinson's disease

Parkinson Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort

Resource links provided by NLM:

Further study details as provided by VA Office of Research and Development:

Primary Outcome Measures:
  • Off-medication/on-stimulation Motor Score of the Unified Parkinson's Disease Rating Scale (UPDRS Part III) [ Time Frame: 7-13 years post implant ] [ Designated as safety issue: No ]

Enrollment: 156
Study Start Date: June 2010
Study Completion Date: April 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Group 1
Cohort of subjects who received DBS as part of the CSP 468 intervention trial, and still have their device working and in place.

Detailed Description:

Parkinson's disease (PD), the second most prevalent neurodegenerative disease (after Alzheimer's disease), affects more than a million Americans and is a common condition in the Veteran population. Although there is currently no cure for the disease, many of the symptoms of the disease can be effectively managed with medications and with deep brain stimulation (DBS). This study seeks to build upon the original CSP#468 protocol by providing an efficient long-term follow-up study. The objectives of this study are to:

determine whether the motor benefits of deep brain stimulation persist beyond two years of follow-up in patients with Parkinson's disease; determine whether the target of stimulation (GPi vs. STN) affects the durability of long-term motor improvement; define the impact of DBS on long-term function and quality of life in patients with Parkinson's disease; identify clinical features that predict favorable or unfavorable long-term outcome; and describe the long-term performance of the DBS devices, including device durability, device explanation rate, neurostimulator replacement frequency, and changes in stimulation parameters to achieve optimum symptom control.


Ages Eligible for Study:   21 Years to 95 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Parkinson's Disease who were enrolled in CSP 468, and received DBS.

Inclusion Criteria:

  • Participant in CSP#468
  • Available and willing to be followed-up according to study protocol

Exclusion Criteria:

  • DBS device explanted or permanently turned off without anticipated resumption of DBS therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01022073

United States, California
UCLA-University of California at Los Angeles(904)
Los Angeles, California, United States, 90095
San Francisco-University of California at San Francisco(905)
San Francisco, California, United States, 94115
San Francisco VA Medical Center, San Francisco, CA
San Francisco, California, United States, 94121
VA Greater Los Angeles Healthcare System, West LA
West Los Angeles, California, United States, 90073
United States, Oregon
VA Medical Center, Portland
Portland, Oregon, United States, 97201
Portland-Oregon Health & science University(906)
Portland, Oregon, United States, 97239
United States, Pennsylvania
VA Medical Center, Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Philadelphia-University of Pennsylvania Health System(901)
Philadelphia, Pennsylvania, United States, 19107
United States, Texas
Houston-Methodist Hospital(903)
Houston, Texas, United States, 77030
Michael E. DeBakey VA Medical Center (152)
Houston, Texas, United States, 77030
United States, Virginia
Hunter Holmes McGuire VA Medical Center
Richmond, Virginia, United States, 23249
Richmond-Medical college of Virginia(902)
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
VA Office of Research and Development
National Institute of Neurological Disorders and Stroke (NINDS)
Study Chair: William J. Marks, MD San Francisco VA Medical Center, San Francisco, CA
  More Information

Additional Information:
Responsible Party: VA Office of Research and Development Identifier: NCT01022073     History of Changes
Other Study ID Numbers: 468F 
Study First Received: November 25, 2009
Last Updated: May 13, 2015
Health Authority: United States: Federal Government

Keywords provided by VA Office of Research and Development:
Deep Brain Stimulation
Subthalamic Nucleus
Globus Pallidus
Parkinson Disease

Additional relevant MeSH terms:
Parkinson Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders processed this record on May 23, 2016